A credit taxonomy author contributions example for a 100+-author clinical trial consortium paper typically cannot assign all 14 CRediT roles to every named individual. Instead, most multi-site consortia assign roles to a small “writing committee,” then credit the remaining site investigators and staff as a collective group — a workable but imperfect compromise between transparency and practicality.
The CRediT taxonomy author contributions example published by most journals — one paper, a handful of authors, each ticking a few of the 14 roles — is straightforward. It falls apart at scale. Multi-site clinical trial consortia routinely publish primary results papers with 50, 200, or even several hundred named contributors across dozens of hospitals, laboratories, and coordinating centres. Applying individual-level CRediT attribution to every one of them is rarely feasible, and the taxonomy itself offers no scaling guidance. This article examines how consortia actually resolve that gap, where the “writing committee” shortcut helps and where it hides real accountability problems, and what research administrators should check before signing off on a consortium submission.
CASRAI originated the CRediT contributor role taxonomy in 2014. The standard is now stewarded by NISO as ANSI/NISO Z39.104-2022, an important distinction for any institution citing CRediT in policy documents.
Contents
- What is the CRediT taxonomy and how is it meant to work?
- Why does individual-level CRediT attribution break down above 100 authors?
- How do multi-site consortia actually assign CRediT roles?
- Answer-first questions on CRediT and large author groups
- What this means for research administrators, funders, and publishers
What is the CRediT taxonomy and how is it meant to work?
The CRediT (Contributor Roles Taxonomy) is a standardised list of 14 role categories — including Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Supervision, and the two Writing roles — used to describe what each named contributor to a research output actually did. Under ANSI/NISO Z39.104-2022, any of the 14 roles can be assigned to more than one contributor, and any contributor can hold more than one role. The taxonomy was designed around conventional author lists of perhaps two to twelve people, where a corresponding author can realistically survey everyone and compile an accurate statement.
CRediT deliberately does not define who qualifies as an author — that remains the domain of criteria such as those published by the International Committee of Medical Journal Editors (ICMJE). CRediT only describes contribution once authorship, or collaborator status, has already been decided elsewhere.
Why does individual-level CRediT attribution break down above 100 authors?
Multi-site clinical trial consortia — platform trials, adaptive-design mega-trials, and large international collaborative groups — routinely list hundreds of contributors: principal investigators at each site, research nurses, statisticians, data monitors, and a central coordinating team. Surveying every one of them individually against 14 role definitions, reconciling disagreements, and keeping the record current through a multi-year trial is an administrative task few coordinating centres can sustain.
Three practical failure points recur:
- Collection burden. A corresponding author cannot manually chase 300 collaborators for role self-declarations before every manuscript revision.
- Role granularity mismatch. Site-level staff often perform a genuinely narrow contribution (patient recruitment, sample handling) that maps to only one or two roles, making individual disclosure administratively disproportionate to its informational value.
- Authorship-vs-collaborator ambiguity. Not every named contributor meets full authorship criteria, and CRediT provides no mechanism of its own for distinguishing the two — that decision is made upstream, under ICMJE or journal-specific rules.
The ICMJE’s Recommendations on the role of authors and contributors state plainly: “When a large multi-author group has conducted the work, the group ideally should decide who will be an author before the work is started and confirm who is an author before submitting the manuscript for publication.” In practice, that decision — not the CRediT assignment — is what most consortia spend their governance effort on.
How do multi-site consortia actually assign CRediT roles?
Three models are in active use across large trial consortia, and each trades transparency against administrative load differently. The dominant compromise is a named writing committee that receives individual CRediT attribution, combined with a collective collaborative group byline (for example, “The [Trial Name] Collaborative Group”) that carries the remaining contributors without a role-by-role breakdown for each person.
| Model | How it works | Transparency | Administrative load |
|---|---|---|---|
| Full individual CRediT | Every named author, however many, completes a role disclosure form | Highest | Unsustainable above roughly 30-50 authors |
| Writing committee + collective group | A small writing committee gets full CRediT roles; remaining contributors are credited as a named collective group, often with individual names and site affiliations in a supplementary appendix | Moderate — accountable core, opaque periphery | Manageable; used by most platform and mega-trials |
| Hybrid tiered disclosure | Writing committee gets full CRediT roles; site principal investigators get a single broad role (e.g. Investigation); frontline staff are acknowledged, not authored | Higher than pure collective model | Moderate, requires a pre-agreed authorship policy |
The ICMJE recommendations also clarify how this interacts with indexing: “the byline of the article identifies who is directly responsible for the manuscript,” and MEDLINE indexes as authors whichever names appear there, while non-author collaborators can still be individually listed and searchable if the journal provides an accompanying note. This means a consortium can preserve individual, searchable credit for site staff even when it does not extend full CRediT role disclosure to each of them — an option under-used by many trial groups.
A pre-agreed authorship and contribution policy, set before a multi-site trial begins recruitment rather than at the manuscript stage, is the single factor that most reliably prevents disputes later. Waiting until submission to decide who was an “author” versus a “collaborator” — and who gets which CRediT role — is the most common cause of delay and disagreement in large consortium publications.
Answer-first questions on CRediT and large author groups
What are examples of author contributions?
Typical author contributions include conceiving the study design, securing funding, recruiting patients, collecting or curating data, performing statistical analysis, writing the first draft, and critically reviewing the final manuscript. Under CRediT, each of these maps to one of 14 defined roles rather than a vague general description.
What should substantial contributions include to be credited as an author?
Per ICMJE criteria, a substantial contribution requires involvement in the work’s conception or design, or the acquisition, analysis, or interpretation of data, combined with drafting or critically revising the manuscript and final approval of the published version. Meeting only one element, such as data collection alone, typically warrants acknowledgement rather than authorship.
How to write an author contribution in a case report?
A case report contribution statement should name each author against the specific tasks they performed — for example, clinical assessment, literature review, drafting, and supervision — using plain, specific language rather than the fuller 14-role CRediT set, which is more suited to larger, multi-method studies with a genuinely divided workload.
What this means for research administrators, funders, and publishers
Research offices supporting multi-site consortium trials should treat CRediT and authorship decisions as a governance item from the protocol stage, not a manuscript-stage formality. A written policy — agreed by the steering committee before recruitment starts — should specify who sits on the writing committee, what threshold of involvement earns collective-group inclusion versus acknowledgement-only, and how the supplementary collaborator list will be maintained and version-controlled across a multi-year trial.
Funders and institutions increasingly use CRediT statements as an input to research assessment, so an opaque “collective group” byline with no supplementary breakdown under-serves early-career site staff who did substantive work but receive no individually attributable, citable role. Publishers that support both a named writing committee and a searchable, named collaborator appendix — rather than a collective name alone — give institutions and funders a materially better evidence trail for exactly this reason.
The underlying tension is not going away: CRediT was built for conventional author teams, and large trial consortia will keep testing its edges. Until a scaling mechanism is formally added to the taxonomy, the writing-committee-plus-named-collaborator-appendix model remains the most defensible practical compromise between individual accountability and administrative reality.
Leave a Reply